8-K - RNLXY - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):January 16, 2025

Renalytix plc

(Exact name of registrant as specified in itsCharter)

England and Wales	001-39387	Not Applicable
(State or other jurisdiction<br><br><br><br><br><br><br><br>of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2 Leman Street

London E1W 9US

United Kingdom

(Address of principal executive offices) (ZipCode)

+44 20 3139 2910

(Registrant’s telephone number, includingarea code)

Not Applicable

(Former name or former address, if changedsince last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. RegulationFD Disclosure

Renalytix plc (the “Company”) has determined that, at December 31, 2024, the last business day of the Company’s most recently completed second fiscal quarter, it qualified as a “foreign private issuer” (“FPI”) as defined in Rule 405 under the Securities Act of 1933, as amended. The Company previously qualified as an FPI. However, since July 1, 2023, the Company had filed as a domestic reporting company. Effective January 1, 2025, the Company will cease filing periodic reports and registration statements with the Securities and Exchange Commission on U.S. domestic issuer forms but will instead file its reports as an FPI.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RENALYTIX PLC
Dated: January 16, 2025	By:	/s/ James McCullough
		James McCullough
		Chief Executive Officer